Finn
NVO Pharmaceuticals · GLP-1 · Obesity care · Diabetes care · Thesis updated November 8, 2026

Volume rebounds while price pressures keep a lid on growth

01 Running thesis

Demand is winning, price is struggling

Novo Nordisk remains a central player in the GLP-1 drug boom. GLP-1 drugs help control blood sugar and reduce appetite. Ozempic treats type 2 diabetes. Wegovy treats obesity. The Wegovy Pill launched in the US in early 2026 and quickly scaled to 1.5 million users worldwide. In the third quarter of 2026, strong patient demand returned the US business to 1 percent growth and drove 8 percent growth internationally.

The bull case relies on multiple shots on goal. The Wegovy Pill continues to find massive demand, aided by Medicare Bridge uptake. CagriSema recently demonstrated a massive 21 percent weight loss at 68 weeks in phase three trials, proving superior to competing drugs. If CagriSema launches successfully in 2027 alongside the new hemophilia drug Frehemgo, Novo can defend a large share of the global market.

The bear case centers on the dollars collected per prescription. Commercial payers are increasingly reluctant to cover obesity medications because the sheer volume of patients drives total health plan costs too high. Ozempic continues to see 10 percent to 15 percent price declines in the US. International markets face generic competition in Canada, and China remains a distinct headwind with its own patent losses approaching.

The current view balances huge reach against intense price competition. Novo has powerful products and a deep pipeline, but it has lost US volume leadership in both diabetes and obesity GLP-1 prescriptions to a rival. The next test is whether cheaper patient access and massive prescription volumes create enough total revenue to drive sustainable growth.

Nov 2026▲Q3 2026 results showed US and international segments returning to growth. Management raised 2026 sales guidance to a range of a 2 percent decline to 2 percent growth, aided by strong CagriSema trial data.
Aug 2026▲Q2 2026 showed Wegovy Pill hitting 1.5 million users globally. The 2026 sales guidance improved to a 0 percent to 6 percent decline, though the ZEUS trial for ziltivekimab failed.
May 2026▲Q1 2026 showed Wegovy Pill above 1 million users and Wegovy High-Dose launched in the US. Guidance improved slightly, but still pointed to a 4 percent to 12 percent adjusted sales decline.
Feb 2026▼The 2026 guide reset the story, with adjusted sales expected to fall 5 percent to 13 percent at constant exchange rates before the later slight improvement. The Wegovy Pill launch was strong, but lower US pricing and Medicaid pressure dominated.
Feb 2026▼The 2025 Form 20-F confirmed that Novo lost the US weekly prescription lead in both diabetes and obesity GLP-1 markets. It also confirmed Wegovy grew to DKK 79 billion in 2025.
Nov 2025→Novo announced major restructuring, a proposed Metsera deal, and added Akero and Omeros assets. Those actions helped the long-term pipeline but came with heavier competition, compounding pressure, and a Wegovy FlexTouch FDA setback.
Aug 2025▲NovoCare cash-channel uptake reached about 10 percent of Wegovy prescriptions, and amycretin data showed 24.3 percent weight loss at 36 weeks. Mike Doustdar also prepared to take over as CEO.
May 2025▼Novo cut full-year sales guidance because US compounding hurt branded GLP-1 penetration. The company responded with a $499 self-pay option, telehealth partners, and a CVS formulary win.
02 Business model

Patents, payers, and volume

Novo makes money by discovering, manufacturing, and selling prescription medicines. Its biggest business is Obesity and Diabetes care. The company reports two business segments: Obesity and Diabetes care, and Rare disease.

The model works best when patented drugs get broad insurance coverage at strong net prices. Novo then sells large volumes through pharmacies, health plans, and national health systems. That model faces pressure in the US, where pharmacy benefit managers, Medicare, Medicaid, and cash-pay channels are pushing prices lower.

Novo trades price for reach to compete. It launched a $499 self-pay Wegovy option through NovoCare and uses Medicare Bridge uptake to drive volume away from compounders. This protects the brand but lowers revenue per prescription. Commercial payers are also fighting back, applying friction to US growth because total costs are compounding rapidly.

Management also controls internal costs. A transformation program under CEO Maziar Mike Doustdar reduced about 9,000 positions to save DKK 8 billion annually. Novo uses deals to widen the pipeline, including a proposed $10 billion acquisition of Metsera to add more obesity assets.

03 Product portfolio

The drugs that matter

Cash cow

Ozempic and Rybelsus

These semaglutide drugs treat type 2 diabetes. Ozempic had more than DKK 127 billion of global sales in 2025, but US pricing faces continued erosion.

Growth engine

Wegovy and Wegovy Pill

Wegovy is Novo's main obesity brand. The Wegovy Pill saw explosive uptake in 2026, reaching 1.5 million users worldwide.

Growth engine

Wegovy High-Dose 7.2 mg

This higher-dose semaglutide obesity product launched in the US in April 2026, offering greater weight loss for patients.

Steady

Insulin products

Insulin is Novo's original business and still matters in diabetes care. It is more mature and faces payer pressure and biosimilar competition.

Steady

Rare disease

This includes growth hormone and haemophilia products. It is much smaller than Obesity and Diabetes care, but it adds some spread beyond GLP-1 drugs.

Option

CagriSema

CagriSema combines semaglutide with cagrilintide. It recently demonstrated superior weight loss against tirzepatide and is tracking for a 2027 global launch.

Option

Frehemgo

A pipeline asset preparing for a global commercial launch in 2027 to treat hemophilia.

04 Business segments

One segment dominates

Obesity and Diabetes care92%flat
Rare disease8%flat

Novo's 2025 Form 20-F says Obesity and Diabetes care made more than 90 percent of sales. The shares below use that disclosure, with the balance shown as Rare disease.

05 Risk factors

What could break the thesis

Lower prices beat higher volume

High impact · High odds

Novo is gaining many new patients, but revenue is challenged because net prices are lower. Ozempic in the US continues to see 10 percent to 15 percent price erosion. If prices fall faster than volumes rise, earnings will stall.

We watchWatch quarterly adjusted sales growth, US realized price comments, and full-year guidance updates.

Competitors keep taking GLP-1 share

High impact · High odds

Novo lost the US weekly prescription lead in both diabetes GLP-1 and obesity GLP-1 markets to a competing product. That changes the story from easy category growth to a price and access fight. A successful CagriSema launch could help close this gap.

We watchWatch US weekly prescription share for Ozempic, Wegovy, and competing GLP-1 drugs.

Payers push back on total cost

High impact · Medium odds

Obesity medicine coverage depends on employers, pharmacy benefit managers, Medicare, and state budgets. Commercial payers are showing reticence to cover these drugs due to staggering volume and total cost trends.

We watchWatch Medicare Part D obesity coverage timing, Medicaid decisions, and major PBM formulary changes.

Semaglutide patents and generics

Medium impact · Medium odds

Novo faces generic semaglutide competition in markets like Canada and Brazil. China specifically represents a continued headwind with its own loss of exclusivity approaching in 2027.

We watchWatch generic semaglutide launches in Canada and Chinese market performance.

Compounders keep patients away

Medium impact · Medium odds

Compounding pharmacies have sold unapproved copies of GLP-1 drugs in the US. Novo is fighting back with cash-pay options, but that also pulls more patients into lower-price channels.

We watchWatch NovoCare cash-channel penetration and legal or FDA actions against compounded semaglutide.
06 Quick answers

In one breath

Is Novo Nordisk still a growth company?

Patient demand is still strong, especially for the Wegovy Pill. Management recently raised 2026 adjusted sales guidance to a range between a 2 percent decline and 2 percent growth.

Why is sales guidance cautious if GLP-1 demand is high?

Novo gets less money per patient in key US channels. Lower self-pay prices, Medicare and Medicaid pressure, rebates, and commercial payer reticence are offsetting volume growth.

What is the main catalyst for Novo Nordisk?

CagriSema is a major pipeline catalyst, especially after showing 21 percent weight loss in recent trials. Investors are also watching the 2027 commercial launches of CagriSema and Frehemgo.

What is the biggest risk for NVO stock?

The biggest risk is that Novo keeps adding patients but cannot protect net price. If that happens, earnings can disappoint even while prescriptions grow.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Novo Nordisk Q3 2026 earnings transcript
  2. Novo Nordisk 2025 Form 20-F, Item 4
  3. Novo Nordisk Q2 2026 earnings transcript
08 Explore the industry

Comparable Drug Manufacturers - General companies

Companies near Novo Nordisk A/S in Finn's Drug Manufacturers - General industry ranking.

Get started with Finn today